{"parse":{"title":"Growth hormone therapy","pageid":622411,"revid":859219593,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em\"><tbody><tr><th colspan=\"2\" style=\"text-align:center;font-size:125%;font-weight:bold;background-color: lightblue\">Growth hormone therapy</th></tr><tr><th scope=\"row\"><a href=\"/wiki/Specialty_(medicine)\" title=\"Specialty (medicine)\">Specialty</a></th><td>\nendocrinologist</td></tr><tr class=\"noprint\"><td colspan=\"2\" style=\"text-align:center\">\n<div style=\"text-align: right;\">&#91;<a href=\"https://www.wikidata.org/wiki/Q5611754\" class=\"extiw\" title=\"d:Q5611754\">edit on Wikidata</a>]</div></td></tr></tbody></table>\n<p><b>Growth hormone therapy</b> refers to the use of <a href=\"/wiki/Growth_hormone\" title=\"Growth hormone\">growth hormone</a> (GH) as a <a href=\"/wiki/Prescription_medication\" class=\"mw-redirect\" title=\"Prescription medication\">prescription medication</a>\u2014it is one form of <a href=\"/wiki/Hormone_therapy\" title=\"Hormone therapy\">hormone therapy</a>. Growth hormone is a <a href=\"/wiki/Peptide_hormone\" title=\"Peptide hormone\">peptide hormone</a> secreted by the <a href=\"/wiki/Pituitary\" class=\"mw-redirect\" title=\"Pituitary\">pituitary</a> gland that stimulates <a href=\"/wiki/Cell_growth\" title=\"Cell growth\">growth</a> and <a href=\"/wiki/Cell_(biology)\" title=\"Cell (biology)\">cell</a> reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by <a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">recombinant DNA</a> technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.\n</p><p>This article describes the history of GH treatment and the current uses and risks arising from GH use. Other articles describe <a href=\"/wiki/Growth_hormone\" title=\"Growth hormone\">GH physiology</a>, diseases of GH excess (<a href=\"/wiki/Acromegaly\" title=\"Acromegaly\">acromegaly</a> and <a href=\"/wiki/Gigantism\" title=\"Gigantism\">pituitary gigantism</a>), <a href=\"/wiki/Growth_hormone_deficiency\" title=\"Growth hormone deficiency\">deficiency</a>, the recent phenomenon of <a href=\"/wiki/HGH_controversies\" title=\"HGH controversies\">HGH controversies</a>, <a href=\"/wiki/Growth_hormone_in_sports\" title=\"Growth hormone in sports\">growth hormone in sports</a>, and <a href=\"/wiki/Bovine_somatotropin\" title=\"Bovine somatotropin\">growth hormone for cows</a>.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Medical_uses\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Medical uses</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#HGH_deficiency_in_children\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">HGH deficiency in children</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#HGH_deficiency_in_adults\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">HGH deficiency in adults</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Other\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Other</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Adverse_effects\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Adverse effects</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#History\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">History</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Extraction_for_treatment\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Extraction for treatment</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Recombinant_human_growth_hormone_(rHGH)\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Recombinant human growth hormone (rHGH)</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#Terminology\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Terminology</span></a></li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Further_reading\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Further reading</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Medical_uses\">Medical uses</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=1\" title=\"Edit section: Medical uses\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"HGH_deficiency_in_children\">HGH deficiency in children</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=2\" title=\"Edit section: HGH deficiency in children\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Growth_hormone_deficiency\" title=\"Growth hormone deficiency\">Growth hormone deficiency</a> is treated by replacing GH.<sup id=\"cite_ref-Humatrope_Label_1-0\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Nutropin_Label_2-0\" class=\"reference\"><a href=\"#cite_note-Nutropin_Label-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Genotropin_Label_3-0\" class=\"reference\"><a href=\"#cite_note-Genotropin_Label-3\">&#91;3&#93;</a></sup>  All GH prescribed in North America, Europe, and most of the rest of the world is a human GH, manufactured by <a href=\"/wiki/Recombinant_DNA_technology\" class=\"mw-redirect\" title=\"Recombinant DNA technology\">recombinant DNA technology</a>. As GH is a large peptide molecule, it must be injected into subcutaneous tissue or muscle to get it into the blood. Nearly painless <a href=\"/wiki/Insulin\" title=\"Insulin\">insulin</a> <a href=\"/wiki/Syringe\" title=\"Syringe\">syringes</a> make this less trying than is usually anticipated, but perceived discomfort is a subjective value.\n</p><p>When treated with GH, a deficient child will begin to grow faster within months. Other benefits may be noticed, such as increased strength, progress in <a href=\"/wiki/Motor_development\" class=\"mw-redirect\" title=\"Motor development\">motor development</a>, and reduction of <a href=\"/wiki/Adipose_tissue\" title=\"Adipose tissue\">body fat</a>. Side-effects of this type of physiologic replacement are quite rare.\n</p><p>Still, costs of treatment in terms of money, effort, and perhaps <a href=\"/wiki/Quality_of_life\" title=\"Quality of life\">quality of life</a> are substantial. Treatment of children usually involves daily injections of growth hormone, usually for as long as the child is growing. Lifelong continuation may be recommended for those most severely deficient as adults. Most <a href=\"/wiki/Pediatric_endocrinologist\" class=\"mw-redirect\" title=\"Pediatric endocrinologist\">pediatric endocrinologists</a> monitor growth and adjust dose every 3\u20134 months. Assessing the psychological value of treatment is difficult, but most children and families are enthusiastic once the physical benefits begin to be seen. Treatment costs vary by country and by size of child, but $US 10,000 to 30,000 a year is common.\n</p><p>Little except the cost of treating severely deficient children is controversial, and most children with severe growth hormone deficiency in the developed world are offered treatment, although most accept.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (January 2009)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"HGH_deficiency_in_adults\">HGH deficiency in adults</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=3\" title=\"Edit section: HGH deficiency in adults\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/The_Endocrine_Society\" class=\"mw-redirect\" title=\"The Endocrine Society\">The Endocrine Society</a> has recommended that adult patients diagnosed with growth hormone deficiency (GHd) be administered an individualized GH treatment regimen.<sup id=\"cite_ref-EndocSoc_4-0\" class=\"reference\"><a href=\"#cite_note-EndocSoc-4\">&#91;4&#93;</a></sup>  With respect to diagnosis, their guidelines state that \"adults patients with structural hypothalamic/pituitary disease, surgery or irradiation in these areas, head trauma, or evidence of other pituitary hormone deficiencies be considered for evaluation for acquired GHd\" and that \"idiopathic GHd in adults is very rare, and stringent criteria are necessary to make this diagnosis. Because in the absence of suggestive clinical circumstances there is a significant false-positive error rate in the response to a single GH stimulation test, we suggest the use of two tests before making this diagnosis.\"<sup id=\"cite_ref-EndocSoc_4-1\" class=\"reference\"><a href=\"#cite_note-EndocSoc-4\">&#91;4&#93;</a></sup>\n</p><p>GH replacement therapy can provide a number of measurable benefits to GH-deficient adults.<sup id=\"cite_ref-Humatrope_Label_1-1\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Nutropin_Label_2-1\" class=\"reference\"><a href=\"#cite_note-Nutropin_Label-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Genotropin_Label_3-1\" class=\"reference\"><a href=\"#cite_note-Genotropin_Label-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-EndocSoc_4-2\" class=\"reference\"><a href=\"#cite_note-EndocSoc-4\">&#91;4&#93;</a></sup>  These include improved <a href=\"/wiki/Bone_density\" title=\"Bone density\">bone density</a>,<sup id=\"cite_ref-pmid17218726_5-0\" class=\"reference\"><a href=\"#cite_note-pmid17218726-5\">&#91;5&#93;</a></sup> increased muscle mass, decrease of <a href=\"/wiki/Adipose_tissue\" title=\"Adipose tissue\">adipose tissue</a>, faster hair and nail growth, strengthened <a href=\"/wiki/Immune_system\" title=\"Immune system\">immune system</a>, increased <a href=\"/wiki/Circulatory_system\" title=\"Circulatory system\">circulatory system</a>, and improved <a href=\"/wiki/Blood_lipid\" class=\"mw-redirect\" title=\"Blood lipid\">blood lipid</a> levels, but long term mortality benefit has not yet been demonstrated.<sup id=\"cite_ref-pmid20373593_6-0\" class=\"reference\"><a href=\"#cite_note-pmid20373593-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-pmid11422104_7-0\" class=\"reference\"><a href=\"#cite_note-pmid11422104-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-pmid10971102_8-0\" class=\"reference\"><a href=\"#cite_note-pmid10971102-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-pmid17284638_9-0\" class=\"reference\"><a href=\"#cite_note-pmid17284638-9\">&#91;9&#93;</a></sup>\n</p><p>A peer-reviewed article published in 2010 indicates that \"Growth hormone (GH) replacement unequivocally benefits growth, body composition, cardiovascular risk factors and quality of life. Less is known about the effects of GH on learning and memory.\"<sup id=\"cite_ref-pmid20696696_10-0\" class=\"reference\"><a href=\"#cite_note-pmid20696696-10\">&#91;10&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Other\">Other</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=4\" title=\"Edit section: Other\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>As of 2004, GH has been approved by the U.S. <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a> for treatment of other conditions:\n</p>\n<ul><li>In adults, wasting (or <a href=\"/wiki/Cachexia\" title=\"Cachexia\">cachexia</a>) caused by AIDS.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup></li>\n<li><a href=\"/wiki/Turner_syndrome\" title=\"Turner syndrome\">Turner syndrome</a> epitomizes the response of non-deficient shortness. At doses 20% higher than those used in GH deficiency, growth accelerates. With several years of treatment the median gain in adult height is about 2\u20133&#160;in (5.1\u20137.6&#160;cm) on this dose. The gains appear to be dose-dependent.<sup id=\"cite_ref-pmid18000090_12-0\" class=\"reference\"><a href=\"#cite_note-pmid18000090-12\">&#91;12&#93;</a></sup> It has been used successfully in toddlers with Turner syndrome,<sup id=\"cite_ref-pmid17595258_13-0\" class=\"reference\"><a href=\"#cite_note-pmid17595258-13\">&#91;13&#93;</a></sup> as well as in older girls.<sup id=\"cite_ref-Humatrope_Label_1-2\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Nutropin_Label_2-2\" class=\"reference\"><a href=\"#cite_note-Nutropin_Label-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Genotropin_Label_3-2\" class=\"reference\"><a href=\"#cite_note-Genotropin_Label-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid17971794_14-0\" class=\"reference\"><a href=\"#cite_note-pmid17971794-14\">&#91;14&#93;</a></sup></li>\n<li><a href=\"/wiki/Short_stature_homeobox_gene\" title=\"Short stature homeobox gene\">Short stature homeobox gene</a> (SHOX) deficiency <sup id=\"cite_ref-Humatrope_Label_1-3\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup></li>\n<li><a href=\"/wiki/Chronic_renal_failure\" class=\"mw-redirect\" title=\"Chronic renal failure\">Chronic renal failure</a> results in many problems, including growth failure. GH treatment for several years both before and after <a href=\"/wiki/Organ_transplant\" class=\"mw-redirect\" title=\"Organ transplant\">transplantation</a> may prevent further deceleration of growth and may narrow the height deficit, though even with treatment net adult height loss may be about 4&#160;in (10&#160;cm)<sup id=\"cite_ref-Humatrope_Label_1-4\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Nutropin_Label_2-3\" class=\"reference\"><a href=\"#cite_note-Nutropin_Label-2\">&#91;2&#93;</a></sup></li>\n<li><a href=\"/wiki/Prader%E2%80%93Willi_syndrome\" title=\"Prader\u2013Willi syndrome\">Prader\u2013Willi syndrome</a>, a generally non-hereditary genetic condition, is a case where GH is prescribed for benefits in addition to height.  GH is one of the treatment options an experienced endocrinologist may use when treating a child with PWS.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>  GH can help children with PWS in height, weight, body mass, strength, and agility.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2008)\">citation needed</span></a></i>&#93;</sup>.  Reports have indicated increase of growth rate (especially in the first year of treatment) and a variety of other positive effects, including improved body composition (higher muscle mass, lower fat mass); improved weight management; increased energy and physical activity; improved strength, agility, and endurance; and improved respiratory function. The Prader-Willi Syndrome Association (USA) recommends that a sleep study be conducted before initiating GH treatment in a child with PWS.  At this time there is no direct evidence of a causative link between growth hormone and the respiratory problems seen in PWS (among both those receiving and those not receiving GH treatment), including sudden death.  A follow-up sleep study after one year of GH treatment may also be indicated.  GH (specifically Pfizer's version, Genotropin) is the only treatment that has received an FDA indication for children with PWS.  The FDA indication only applies to children.<sup id=\"cite_ref-Genotropin_Label_3-3\" class=\"reference\"><a href=\"#cite_note-Genotropin_Label-3\">&#91;3&#93;</a></sup></li>\n<li>Children short because of <a href=\"/wiki/Intrauterine_growth_retardation\" class=\"mw-redirect\" title=\"Intrauterine growth retardation\">intrauterine growth retardation</a> are small for gestational age at birth for a variety of reasons. If early <a href=\"/wiki/Catch-up_growth\" class=\"mw-redirect\" title=\"Catch-up growth\">catch-up growth</a> does not occur and their heights remain below the third percentile by 2 or 3 years of age, adult height is likely to be similarly low. High-dose GH treatment has been shown to accelerate growth, but data on long term benefits and risks are limited.<sup id=\"cite_ref-Humatrope_Label_1-5\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Genotropin_Label_3-4\" class=\"reference\"><a href=\"#cite_note-Genotropin_Label-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid17823537_16-0\" class=\"reference\"><a href=\"#cite_note-pmid17823537-16\">&#91;16&#93;</a></sup></li>\n<li><a href=\"/wiki/Idiopathic_short_stature\" title=\"Idiopathic short stature\">Idiopathic short stature</a> (ISS) is one of the most controversial indications for GH as pediatric endocrinologists do not agree on its definition, <a href=\"/wiki/Medical_diagnosis\" title=\"Medical diagnosis\">diagnostic criteria</a>, or limits.<sup id=\"cite_ref-pmid18040291_17-0\" class=\"reference\"><a href=\"#cite_note-pmid18040291-17\">&#91;17&#93;</a></sup> The term has been applied to children with severe unexplained shortness that will result in an adult height below the 3rd percentile. In the late 1990s, the pharmaceutical manufacturer <a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly and Company</a> sponsored trials of their brand of <a href=\"/wiki/RHGH\" class=\"mw-redirect\" title=\"RHGH\">rHGH</a> (Humatrope) in children with extreme ISS, those at least 2.25 standard deviations below mean (in the lowest 1.2 percent of the population). These boys and girls appeared to be headed toward heights of less than 63\" (160&#160;cm) and 59\" (150&#160;cm) respectively. They were treated for about 4 years and gained 1.5\u20133&#160;in (3.8\u20137.6&#160;cm) in adult height. Controversy has arisen as to whether all of these children were truly \"short normal\" children, since the average <a href=\"/wiki/IGF1\" class=\"mw-redirect\" title=\"IGF1\">IGF1</a> was low. Approval of HGH for the treatment of this extreme degree of shortness led to an increase in the number of parents seeking its use to make otherwise normal children a little taller.<sup id=\"cite_ref-Humatrope_Label_1-6\" class=\"reference\"><a href=\"#cite_note-Humatrope_Label-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Nutropin_Label_2-4\" class=\"reference\"><a href=\"#cite_note-Nutropin_Label-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Genotropin_Label_3-5\" class=\"reference\"><a href=\"#cite_note-Genotropin_Label-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid17519313_18-0\" class=\"reference\"><a href=\"#cite_note-pmid17519313-18\">&#91;18&#93;</a></sup></li></ul>\n<h2><span class=\"mw-headline\" id=\"Adverse_effects\">Adverse effects</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=5\" title=\"Edit section: Adverse effects\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><i>The New England Journal of Medicine</i> published two editorials in 2003 expressing concern about <a href=\"/wiki/Off-label_use\" title=\"Off-label use\">off-label uses</a> of HGH and the proliferation of advertisements for \"HGH-Releasing\" dietary supplements, and emphasized that there is no evidence that use of HGH in healthy adults or in geriatric patients is safe and effective - and especially emphasized that risks of long-term HGH treatment are unknown. One editorial was by Jeffrey M. Drazen, M.D., the editor-in-chief of the journal;<sup id=\"cite_ref-pmid12606730_19-0\" class=\"reference\"><a href=\"#cite_note-pmid12606730-19\">&#91;19&#93;</a></sup> the other one<sup id=\"cite_ref-pmid12606731_20-0\" class=\"reference\"><a href=\"#cite_note-pmid12606731-20\">&#91;20&#93;</a></sup> was by Dr. Mary Lee Vance, who provided the NEJM's editorial original, cautious comment on a much cited 1990 study on the use of HGH in geriatric patients with low growth hormone levels.\n</p><p>A small but controlled study of GH given to severely ill adults in an <a href=\"/wiki/Intensive_care\" class=\"mw-redirect\" title=\"Intensive care\">intensive care</a> unit setting for the purpose of increasing strength and reducing the muscle wasting of critical illness showed a higher mortality rate for the patients having received GH.<sup id=\"cite_ref-pmid10477776_21-0\" class=\"reference\"><a href=\"#cite_note-pmid10477776-21\">&#91;21&#93;</a></sup> The reason is unknown, but GH is now rarely used in ICU patients unless they have severe growth hormone deficiency.\n</p><p>GH treatment usually decreases <a href=\"/wiki/Insulin_sensitivity\" class=\"mw-redirect\" title=\"Insulin sensitivity\">insulin sensitivity</a>,<sup id=\"cite_ref-pmid12679422_22-0\" class=\"reference\"><a href=\"#cite_note-pmid12679422-22\">&#91;22&#93;</a></sup> but some studies showed no evidence for increased <a href=\"/wiki/Diabetes_mellitus\" title=\"Diabetes mellitus\">diabetes</a> incidence in GH-treated adult hypopituitary patients.<sup id=\"cite_ref-pmid21543424_23-0\" class=\"reference\"><a href=\"#cite_note-pmid21543424-23\">&#91;23&#93;</a></sup>\n</p><p>In past it was believed that GH treatment could increase the <a href=\"/wiki/Cancer\" title=\"Cancer\">cancer</a> risk; a large study recently concluded that \"With relatively short follow-up, the overall primary cancer risk in 6840 patients receiving GH as adults was not increased. Elevated SIRs (which is risk of getting cancer) were found for subgroups in the USA cohort defined by age &lt;35 years or childhood onset GH deficiency.\"<sup id=\"cite_ref-pmid21646285_24-0\" class=\"reference\"><a href=\"#cite_note-pmid21646285-24\">&#91;24&#93;</a></sup>\n</p><p>The FDA issued a Safety Alert in August 2011, communicating the fact that a French study found that persons with certain kinds of short stature (idiopathic <a href=\"/wiki/Growth_hormone_deficiency\" title=\"Growth hormone deficiency\">growth hormone deficiency</a> and idiopathic or gestational <a href=\"/wiki/Short_stature\" title=\"Short stature\">short stature</a>) treated with recombinant human growth hormone during childhood and who were followed over a long period of time, were at a small increased risk of death when compared to individuals in the general population of France.<sup id=\"cite_ref-url_FDA_somatropin_Safety_Review_25-0\" class=\"reference\"><a href=\"#cite_note-url_FDA_somatropin_Safety_Review-25\">&#91;25&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=6\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Perhaps the most famous person who exemplified the appearance of untreated congenital <a href=\"/wiki/Growth_hormone_deficiency\" title=\"Growth hormone deficiency\">growth hormone deficiency</a> was <a href=\"/wiki/General_Tom_Thumb\" title=\"General Tom Thumb\">Charles Sherwood Stratton</a> (1838\u20131883), who was exhibited by <a href=\"/wiki/P._T._Barnum\" title=\"P. T. Barnum\">P. T. Barnum</a> as <a href=\"/wiki/General_Tom_Thumb\" title=\"General Tom Thumb\">General Tom Thumb</a>, and married Lavinia Warren. Pictures of the couple show the typical adult features of untreated severe growth hormone deficiency. Despite the severe shortness, limbs and trunks are proportional.\n</p><p>Like many other nineteenth-century medical terms that lost precise meaning as they gained wider currency, \u201c<a href=\"/wiki/Midget\" title=\"Midget\">midget</a>\u201d, as a term for someone with extreme proportional shortness, acquired pejorative connotations and is no longer used in medical contexts.\n</p><p>By the middle of the twentieth century, endocrinologists understood the clinical features of growth hormone deficiency. GH is a protein hormone, like <a href=\"/wiki/Insulin\" title=\"Insulin\">insulin</a>, which had been purified from pig and cow <a href=\"/wiki/Pancreas\" title=\"Pancreas\">pancreases</a> for treatment of type 1 diabetes since the 1920s. However, pig and cow GH did not work at all in humans, due to greater species-to-species variation of molecular structure (i.e., insulin is considered more \"evolutionarily conserved\" than GH).\n</p>\n<h3><span class=\"mw-headline\" id=\"Extraction_for_treatment\">Extraction for treatment</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=7\" title=\"Edit section: Extraction for treatment\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Extracted growth hormone was used since the late 1950s until the late 1980s when its use was replaced by recombinant GH.\n</p><p>In the late 1950s, Maurice Raben purified enough GH from human <a href=\"/wiki/Pituitary_gland\" title=\"Pituitary gland\">pituitary glands</a> to successfully treat a GH-deficient boy. A few endocrinologists began to help parents of severely GH-deficient children to make arrangements with local <a href=\"/wiki/Pathologist\" class=\"mw-redirect\" title=\"Pathologist\">pathologists</a> to collect human pituitary glands after removal at <a href=\"/wiki/Autopsy\" title=\"Autopsy\">autopsy</a>. Parents would then contract with a <a href=\"/wiki/Biochemistry\" title=\"Biochemistry\">biochemist</a> to purify enough growth hormone to treat their child. Few families could manage such a complicated undertaking.\n</p><p>In 1960, the <a href=\"/w/index.php?title=National_Pituitary_Agency&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"National Pituitary Agency (page does not exist)\">National Pituitary Agency</a> was formed as a branch of the U.S. <a href=\"/wiki/National_Institutes_of_Health\" title=\"National Institutes of Health\">National Institutes of Health</a>. The purpose of this agency was to supervise the collection of human pituitary glands when autopsies were performed, arrange for large-scale extraction and purification of GH, and distribute it to a limited number of pediatric endocrinologists for treating GH-deficient children under research protocols. Canada, UK, Australia, New Zealand, France, Israel, and other countries establish similar government-sponsored agencies to collect pituitaries, purify GH, and distribute it for treatment of severely GH-deficient children.\n</p><p>Supplies of this \u201ccadaver growth hormone\u201d were limited, and only the most severely deficient children were treated. From 1963 to 1985 about 7700 children in the U.S. and 27,000 children worldwide were given GH extracted from human pituitary glands to treat severe GH deficiency. Physicians trained in the relatively new specialty of <a href=\"/wiki/Pediatric_endocrinology\" title=\"Pediatric endocrinology\">pediatric endocrinology</a> provided most of this care, but in the late 1960s there were only a hundred of these physicians in a few dozen of the largest university medical centers around the world.\n</p><p>In 1976, physicians became aware that <a href=\"/wiki/Creutzfeldt%E2%80%93Jakob_disease\" title=\"Creutzfeldt\u2013Jakob disease\">Creutzfeldt\u2013Jakob disease</a> could be transmitted by <a href=\"/wiki/Neurosurgery\" title=\"Neurosurgery\">neurosurgical</a> procedures and <a href=\"/wiki/Cornea_transplantation\" class=\"mw-redirect\" title=\"Cornea transplantation\">cornea transplantation</a>. CJD is a rapidly fatal <a href=\"/wiki/Dementia\" title=\"Dementia\">dementing disease</a> of the brain also known as <a href=\"/wiki/Spongiform_encephalopathy\" class=\"mw-redirect\" title=\"Spongiform encephalopathy\">spongiform encephalopathy</a>, related to \u201c<a href=\"/wiki/Mad_cow_disease\" class=\"mw-redirect\" title=\"Mad cow disease\">mad cow disease</a>\u201d.\n</p><p>In 1977, the NPA GH extraction and purification procedure was refined and improved.\n</p><p>A shortage of available cadaver GH worsened in the late 1970s as the autopsy rate in the U.S. declined, while the number of pediatric endocrinologists able to diagnose and treat GH deficiency increased. GH was \"rationed.\" Often, treatment would be stopped when a child reached an arbitrary minimal height, such as 5&#160;ft 0&#160;in (1.52&#160;m). Children who were short for reasons other than severe GH deficiency were lied to and told that they would not benefit from treatment. Only those pediatric endocrinologists that remained at university medical centers with departments able to support a research program had access to NPA growth hormone.\n</p><p>In the late 1970s, a Swedish pharmaceutical company, Kabi, contracted with a number of hospitals in Europe to buy pituitary glands for the first commercial GH product, Crescormon. Although an additional source of GH was welcomed, Crescormon was greeted with ambivalence by pediatric endocrinologists in the United States. The first concern was that Kabi would begin to purchase pituitaries in the U.S., which would quickly undermine the NPA, which relied on a donation system like blood transfusion.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2017)\">citation needed</span></a></i>&#93;</sup> As the number of autopsies continued to shrink, would pathologists sell pituitaries to a higher bidder? The second offense was Kabi-Pharmacia\u2019s marketing campaign, which was directed at <a href=\"/wiki/Primary_care_physician\" title=\"Primary care physician\">primary care physicians</a> under the slogan, \u201cNow, you determine the need,\u201d implying that the services of a specialist were not needed for growth hormone treatment anymore and that any short child might be a candidate for treatment. Although the Crescormon controversy in the U.S. is long forgotten, Kabi\u2019s pituitary purchase program continued to generate scandal in Europe as recently as 2000.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2017)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h3><span id=\"Recombinant_human_growth_hormone_.28rHGH.29\"></span><span class=\"mw-headline\" id=\"Recombinant_human_growth_hormone_(rHGH)\">Recombinant human growth hormone (rHGH)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=8\" title=\"Edit section: Recombinant human growth hormone (rHGH)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 1981, the new American corporation Genentech, after collaboration with Kabi, developed and started trials of recombinant human growth hormone (rHGH) made by a new technology (<a href=\"/wiki/Recombinant_DNA_technology\" class=\"mw-redirect\" title=\"Recombinant DNA technology\">recombinant DNA</a>) in which human <a href=\"/wiki/Gene\" title=\"Gene\">genes</a> were inserted into bacteria so that they could produce unlimited amounts of the protein. Because this was new technology, approval was deferred as lengthy safety trials continued over the next four years.\n</p><p>In 1985, four young adults in the U.S. having received NPA growth hormone in the 1960s developed CJD (<a href=\"/wiki/Creutzfeldt%E2%80%93Jakob_disease\" title=\"Creutzfeldt\u2013Jakob disease\">Creutzfeldt\u2013Jakob disease</a>). The connection was recognized within a few months, and use of human pituitary GH rapidly ceased. Between 1985 and 2003, a total of 26 cases of CJD occurred in adults having received NPA GH before 1977 (out of 7700), comparable numbers of cases occurred around the world. By 2003 there had been no cases in people who received only GH purified by the improved 1977 methods.\n</p><p>Discontinuation of human cadaver growth hormone led to rapid Food and Drug Administration approval of Genentech\u2019s recombinant human growth hormone, which was introduced in 1985 as <b>Protropin</b> in the United States. Although this previously scarce commodity was suddenly available in \"bucketfuls\", the price of treatment (US$10,000\u201330,000 per year) was the highest at the time. Genentech justified it by the prolonged research and development investment, <a href=\"/wiki/Orphan_drug\" title=\"Orphan drug\">orphan drug</a> status, and a pioneering <a href=\"/wiki/Postmarketing_surveillance\" title=\"Postmarketing surveillance\">post-marketing surveillance</a> registry for tracking safety and effectiveness (<a href=\"/wiki/National_Cooperative_Growth_Study\" title=\"National Cooperative Growth Study\">National Cooperative Growth Study</a>).\n</p><p>Within a few years, GH treatment had become more common and competitors entered the market. <a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly</a> launched a competing natural sequence growth hormone (Humatrope). Pharmacia (formerly Kabi, now <a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a>) introduced Genotropin. <a href=\"/wiki/Novo_Nordisk\" title=\"Novo Nordisk\">Novo Nordisk</a> introduced Norditropin. <a href=\"/wiki/Serono\" title=\"Serono\">Serono</a> (now EMD Serono) introduced Saizen and Serostim. Ferring has introduced Zomacton.  Genentech eventually introduced another HGH product, Nutropin, and stopped making Protropin in 2004.  Price competition had begun. Teva, which is primarily a generics company, has introduced Tev-tropin.   Chinese companies have entered the market as well and have introduced more pricing competition: NeoGenica BioScience Ltd. introduced Hypertropin, GeneScience introduced Jintropin, Anhui Anke Biotechnology introduced Ansomone, Shanghai United Kefei Biotechnology introduced Kefei HGH,<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> and Hygene BioPharm introduced Hygetropin.  These are all recombinant human growth hormone products and they have competed with various marketing strategies. Most children with severe deficiency in the developed world are now likely to have access to a pediatric endocrinologist and be diagnosed and offered treatment.\n</p><p><a href=\"/wiki/Pediatric_endocrinology\" title=\"Pediatric endocrinology\">Pediatric endocrinology</a> became a recognizable specialty in the 1950s, but did not reach board status in the U.S. until the late 1970s. Even 10 years later, as a cognitive, procedureless specialty dealing with mostly rare diseases, it was one of the smallest, lowest-paid, and more obscure of the medical specialities<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2011)\">citation needed</span></a></i>&#93;</sup>. Pediatric endocrinologists were the only physicians interested in the arcana of GH metabolism and children\u2019s growth<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2011)\">citation needed</span></a></i>&#93;</sup>, but their previously academic arguments took on new practical significance with major financial implications.\n</p><p>The major scientific arguments dated back to the days of GH scarcity:\n</p>\n<ul><li>Everyone agrees on the nature and diagnosis of severe <a href=\"/wiki/Growth_hormone_deficiency\" title=\"Growth hormone deficiency\">GH deficiency</a>, but what are the edges and variations?</li>\n<li>How should marked <a href=\"/wiki/Delayed_puberty\" title=\"Delayed puberty\">constitutional delay</a> be distinguished from partial GH deficiency?</li>\n<li>To what extent is \"normal <a href=\"/wiki/Short_stature\" title=\"Short stature\">shortness</a>\" a matter of short children naturally making less growth hormone?</li>\n<li>Can a child make GH in response to a stimulation test but fail to make enough in \"daily life\" to grow normally?</li>\n<li>If a stimulation test is used to define deficiency, what GH cutoff should be used to define normal?</li></ul>\n<p>It was the <a href=\"/wiki/Bioethics\" title=\"Bioethics\">ethical</a> questions that were new. Is GH not a wise use of finite healthcare resources, or is the physician\u2019s primary responsibility to the patient? If GH is given to most extremely short children to make them taller, will the definition of \u201cextremely short\u201d simply rise, negating the expected social benefit? If GH is given to short children whose parents can afford it, will shortness become a permanent mark of lower social origins? More of these issues are outlined in the ethics section. Whole meetings were devoted to these questions; pediatric endocrinology had become a specialty with its own <a href=\"/wiki/Bioethics\" title=\"Bioethics\">bioethics</a> issues.\n</p><p>Despite the price, the 1990s became an era of experimentation to see what else growth hormone could help. The medical literature of the decade contains hundreds of reports of small trials of GH use in nearly every type of growth failure and shortness imaginable. In most cases, the growth responses were modest<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2011)\">citation needed</span></a></i>&#93;</sup>. For conditions with a large enough potential market, more rigorous trials were sponsored by pharmaceutical companies that were making growth hormone to achieve approval to market for those specific indications. <a href=\"/wiki/Turner_syndrome\" title=\"Turner syndrome\">Turner syndrome</a> and <a href=\"/wiki/Chronic_renal_failure\" class=\"mw-redirect\" title=\"Chronic renal failure\">chronic renal failure</a> were the first of these \u201cnonGH-deficient causes of shortness\u201d to receive <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">FDA</a> approval for GH treatment, and <a href=\"/wiki/Prader-Willi_syndrome\" class=\"mw-redirect\" title=\"Prader-Willi syndrome\">Prader-Willi syndrome</a> and <a href=\"/wiki/Intrauterine_growth_retardation\" class=\"mw-redirect\" title=\"Intrauterine growth retardation\">intrauterine growth retardation</a> followed. Similar expansion of use occurred in Europe.\n</p><p>One obvious potential market was adult GH deficiency. By the mid-1990s, several GH companies had sponsored or publicized research into the <a href=\"/wiki/Quality_of_life\" title=\"Quality of life\">quality of life</a> of adults with severe GH deficiency<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2011)\">citation needed</span></a></i>&#93;</sup>. Most were people having been treated with GH in childhood for severe deficiency<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2011)\">citation needed</span></a></i>&#93;</sup>.  Although the injections are painless, many of them had been happy to leave injections behind as they reached final heights in the low-normal range<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2011)\">citation needed</span></a></i>&#93;</sup>. However, as adults in their 30s and 40s, these people, who had been children with growth hormone deficiency, were now adults with growth hormone deficiency and had more than their share of common adult problems: reduced physical, mental, and social energy, excess adipose and diminished muscle, diminished libido, poor bone density, higher cholesterol levels, and higher rates of cardiovascular disease. Research trials soon confirmed that a few months of GH could improve nearly all of these parameters. However, despite marketing efforts, most GH-deficient adults remain untreated.\n</p><p>Though GH use was slow to be accepted among adults with GH deficiency, similar research to see if GH treatment could slow or reverse some of the similar effects of aging attracted much public interest. The most publicized trial was reported by Daniel Rudman in 1990.<sup id=\"cite_ref-pmid2355952_27-0\" class=\"reference\"><a href=\"#cite_note-pmid2355952-27\">&#91;27&#93;</a></sup> As with other types of hormone supplementation for aging (<a href=\"/wiki/Testosterone_(medication)\" title=\"Testosterone (medication)\">testosterone</a>, <a href=\"/wiki/Estrogen\" title=\"Estrogen\">estrogen</a>, <a href=\"/wiki/Dehydroepiandrosterone\" title=\"Dehydroepiandrosterone\">DHEA</a>), confirmation of benefit and accurate understanding of risks has been only slowly evolving.\n</p><p>In 1997, Ronald Klatz of the <a href=\"/wiki/American_Academy_of_Anti-Aging_Medicine\" title=\"American Academy of Anti-Aging Medicine\">American Academy of Anti-Aging Medicine</a> published <i>Grow Young With HGH: The Amazing Medically Proven Plan To Reverse the Effects Of Aging</i>,<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> an uncritical touting of GH as the answer to aging.<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span></span></sup><sup id=\"cite_ref-30\" class=\"reference\"><a href=\"#cite_note-30\">&#91;30&#93;</a></sup> This time, the internet amplified the proposition and spawned a hundred frauds and scams. However, their adoption of the \"HGH\" term has provided an easy way to distinguish the hype from the evidence.  In 2003, growth hormone hit the news again, when the US FDA granted <a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly</a> approval to market Humatrope for the treatment of <a href=\"/wiki/Idiopathic_short_stature\" title=\"Idiopathic short stature\">idiopathic short stature</a>. The indication was controversial for several reasons, the primary one being the difficulty in defining extreme shortness with normal test results as a disease rather than the extreme end of the normal height range<sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup>\n</p><p>Recombinant growth hormone available in the U.S. (and their manufacturers) included <i>Nutropin</i> (<a href=\"/wiki/Genentech\" title=\"Genentech\">Genentech</a>), <i>Humatrope</i> (<a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly and Company</a>), <i>Genotropin</i> (<a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a>), <i>Norditropin</i> (<a href=\"/wiki/Novo_Nordisk\" title=\"Novo Nordisk\">Novo Nordisk</a>), <i>Tev-Tropin</i> (<a href=\"/wiki/Teva_Pharmaceutical_Industries\" title=\"Teva Pharmaceutical Industries\">Teva</a>) and <i><a href=\"/wiki/Saizen\" title=\"Saizen\">Saizen</a></i> (<a href=\"/wiki/Merck_Serono\" title=\"Merck Serono\">Merck Serono</a>). The products are nearly identical in composition, efficacy, and cost, varying primarily in the formulations and delivery devices.\n</p>\n<h2><span class=\"mw-headline\" id=\"Terminology\">Terminology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=9\" title=\"Edit section: Terminology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><b>Growth hormone</b> (GH l) is also called somatotropin (British: somatotrophin). The human form of growth hormone is known as human growth hormone, or hGH (ovine growth hormone, or sheep growth hormone, is abbreviated oGH). GH can refer either to the natural hormone produced by the pituitary (somatotropin), or biosynthetic GH for therapy.\n</p><p><b>Cadaver growth hormone</b> is the term for GH extracted from the pituitary glands of human <a href=\"/wiki/Cadaver\" title=\"Cadaver\">cadavers</a> between 1960 and 1985 for therapy of deficient children. In the U.S., cadaver GH, also referred to as <b>NPA growth hormone</b>, was provided by the National Pituitary Agency, and by other national programs and commercial firms as well. In 1985 it was associated with the development of <a href=\"/wiki/Creutzfeldt%E2%80%93Jakob_disease\" title=\"Creutzfeldt\u2013Jakob disease\">Creutzfeldt\u2013Jakob disease</a>, and was withdrawn from use.\n</p><p><b>RHGH</b> (rHGH, rhGH) refers to <a href=\"/wiki/Recombinant_DNA_technology\" class=\"mw-redirect\" title=\"Recombinant DNA technology\">recombinant</a> human growth hormone, that is, somatropin (<a href=\"/wiki/International_nonproprietary_name\" title=\"International nonproprietary name\">INN</a>). Its amino acid sequence is identical with that of endogenous human GH.\n</p><p>It is coincidental that RHGH also refers to <a href=\"/wiki/Rhesus_macaque\" title=\"Rhesus macaque\">rhesus monkey</a> GH (RhGH), using the accepted naming convention of <a href=\"/wiki/Rh_blood_group_system\" title=\"Rh blood group system\"><i>Rh</i> for <i>rhesus</i></a>. Rhesus <a href=\"/wiki/Growth_hormone\" title=\"Growth hormone\">growth hormone</a> was never used by physicians to treat human patients, but rhesus GH was part of the lore of the underground <a href=\"/wiki/Anabolic_steroid\" title=\"Anabolic steroid\">anabolic steroid</a> community in those years, and fraudulent versions may have been bought and sold in gyms.\n</p><p><b>met-GH</b> refers to <a href=\"/wiki/Methionine\" title=\"Methionine\">methionyl</a>\u2013growth hormone, that is, <a href=\"/wiki/Somatrem\" title=\"Somatrem\">somatrem</a> (INN). This was the first recombinant GH product marketed (trade name Protropin by Genentech). It had the same <a href=\"/wiki/Amino_acid\" title=\"Amino acid\">amino acid</a> sequence as human GH with an extra <a href=\"/wiki/Methionine\" title=\"Methionine\">methionine</a> at the end of the chain to facilitate the manufacturing process. It was discontinued in 2004.<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup>\n</p><p><b>rBST</b> refers to recombinant <a href=\"/wiki/Bovine_somatotropin\" title=\"Bovine somatotropin\">bovine somatotropin</a> (cow growth hormone), or recombinant bovine GH (rbGH, RBGH).\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=10\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-Humatrope_Label-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Humatrope_Label_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Humatrope_Label_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Humatrope_Label_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Humatrope_Label_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Humatrope_Label_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Humatrope_Label_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Humatrope_Label_1-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019640s068lbl.pdf\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019640s068lbl.pdf</a></span>\n</li>\n<li id=\"cite_note-Nutropin_Label-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Nutropin_Label_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Nutropin_Label_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Nutropin_Label_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Nutropin_Label_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Nutropin_Label_2-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.gene.com/gene/products/information/opportunistic/nutropin/insert.jsp\">http://www.gene.com/gene/products/information/opportunistic/nutropin/insert.jsp</a></span>\n</li>\n<li id=\"cite_note-Genotropin_Label-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Genotropin_Label_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Genotropin_Label_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Genotropin_Label_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Genotropin_Label_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Genotropin_Label_3-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Genotropin_Label_3-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.pfizer.com/files/products/uspi_genotropin.pdf\">http://www.pfizer.com/files/products/uspi_genotropin.pdf</a></span>\n</li>\n<li id=\"cite_note-EndocSoc-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-EndocSoc_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-EndocSoc_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-EndocSoc_4-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">Molitch ME et al. (2011) <a rel=\"nofollow\" class=\"external text\" href=\"http://www.endo-society.org/guidelines/upload/Evaluation-treatment-of-Adult-Growth-Hormone-Deficiency-Clinical-Practice-Guideline-NonCME.pdf\">Evaluation and Treatment of Adult Growth Hormone Deficiency:An Endocrine Society Clinical Practice Guideline</a> The Endocrine Society, 2011.  First published in Journal of Clinical Endocrinology &amp; Metabolism, 96(6):1587\u20131609.</span>\n</li>\n<li id=\"cite_note-pmid17218726-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17218726_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">G\u00f6therstr\u00f6m G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J (January 2007). \"Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency\". <i>Eur. J. Endocrinol</i>. <b>156</b> (1): 55\u201364. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1530/eje.1.02317\">10.1530/eje.1.02317</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17218726\">17218726</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eur.+J.+Endocrinol.&amp;rft.atitle=Ten-year+GH+replacement+increases+bone+mineral+density+in+hypopituitary+patients+with+adult+onset+GH+deficiency&amp;rft.volume=156&amp;rft.issue=1&amp;rft.pages=55-64&amp;rft.date=2007-01&amp;rft_id=info%3Adoi%2F10.1530%2Feje.1.02317&amp;rft_id=info%3Apmid%2F17218726&amp;rft.aulast=G%C3%B6therstr%C3%B6m&amp;rft.aufirst=G&amp;rft.au=Bengtsson%2C+BA&amp;rft.au=Bosaeus%2C+I&amp;rft.au=Johannsson%2C+G&amp;rft.au=Svensson%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid20373593-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid20373593_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Alexopoulou O, Abs R, Maiter D (2010). \"Treatment of adult growth hormone deficiency: who, why and how? A review\". <i>Acta Clin Belg</i>. <b>65</b> (1): 13\u201322. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1179/acb.2010.002\">10.1179/acb.2010.002</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20373593\">20373593</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Clin+Belg&amp;rft.atitle=Treatment+of+adult+growth+hormone+deficiency%3A+who%2C+why+and+how%3F+A+review&amp;rft.volume=65&amp;rft.issue=1&amp;rft.pages=13-22&amp;rft.date=2010&amp;rft_id=info%3Adoi%2F10.1179%2Facb.2010.002&amp;rft_id=info%3Apmid%2F20373593&amp;rft.aulast=Alexopoulou&amp;rft.aufirst=O&amp;rft.au=Abs%2C+R&amp;rft.au=Maiter%2C+D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid11422104-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid11422104_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP (June 2001). \"Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement\". <i>Clin. Endocrinol</i>. <b>54</b> (6): 709\u201317. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1046/j.1365-2265.2001.01275.x\">10.1046/j.1365-2265.2001.01275.x</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11422104\">11422104</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin.+Endocrinol.&amp;rft.atitle=Body+composition+and+quality+of+life+in+adults+with+growth+hormone+deficiency%3B+effects+of+low-dose+growth+hormone+replacement&amp;rft.volume=54&amp;rft.issue=6&amp;rft.pages=709-17&amp;rft.date=2001-06&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2265.2001.01275.x&amp;rft_id=info%3Apmid%2F11422104&amp;rft.aulast=Ahmad&amp;rft.aufirst=AM&amp;rft.au=Hopkins%2C+MT&amp;rft.au=Thomas%2C+J&amp;rft.au=Ibrahim%2C+H&amp;rft.au=Fraser%2C+WD&amp;rft.au=Vora%2C+JP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid10971102-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid10971102_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Savine R, S\u00f6nksen P (2000). \"Growth hormone - hormone replacement for the somatopause?\". <i>Horm. Res</i>. 53 Suppl 3: 37\u201341. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1159/000023531\">10.1159/000023531</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/10971102\">10971102</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Horm.+Res.&amp;rft.atitle=Growth+hormone+-+hormone+replacement+for+the+somatopause%3F&amp;rft.volume=53+Suppl+3&amp;rft.pages=37-41&amp;rft.date=2000&amp;rft_id=info%3Adoi%2F10.1159%2F000023531&amp;rft_id=info%3Apmid%2F10971102&amp;rft.aulast=Savine&amp;rft.aufirst=R&amp;rft.au=S%C3%B6nksen%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17284638-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17284638_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">G\u00f6therstr\u00f6m G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J (April 2007). \"A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults\". <i>J. Clin. Endocrinol. Metab</i>. <b>92</b> (4): 1442\u20135. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1210/jc.2006-1487\">10.1210/jc.2006-1487</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17284638\">17284638</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Clin.+Endocrinol.+Metab.&amp;rft.atitle=A+10-year%2C+prospective+study+of+the+metabolic+effects+of+growth+hormone+replacement+in+adults&amp;rft.volume=92&amp;rft.issue=4&amp;rft.pages=1442-5&amp;rft.date=2007-04&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2006-1487&amp;rft_id=info%3Apmid%2F17284638&amp;rft.aulast=G%C3%B6therstr%C3%B6m&amp;rft.aufirst=G&amp;rft.au=Bengtsson%2C+BA&amp;rft.au=Bosaeus%2C+I&amp;rft.au=Johannsson%2C+G&amp;rft.au=Svensson%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid20696696-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid20696696_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Wass JA, Reddy R (November 2010). \"Growth hormone and memory\". <i>J. Endocrinol</i>. <b>207</b> (2): 125\u20136. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1677/JOE-10-0126\">10.1677/JOE-10-0126</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20696696\">20696696</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Endocrinol.&amp;rft.atitle=Growth+hormone+and+memory&amp;rft.volume=207&amp;rft.issue=2&amp;rft.pages=125-6&amp;rft.date=2010-11&amp;rft_id=info%3Adoi%2F10.1677%2FJOE-10-0126&amp;rft_id=info%3Apmid%2F20696696&amp;rft.aulast=Wass&amp;rft.aufirst=JA&amp;rft.au=Reddy%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.serostim.com/Files/PDFs/Full_Prescribing_Information.pdf\">http://www.serostim.com/Files/PDFs/Full_Prescribing_Information.pdf</a></span>\n</li>\n<li id=\"cite_note-pmid18000090-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid18000090_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Bolar K, Hoffman AR, Maneatis T, Lippe B (February 2008). \"Long-term safety of recombinant human growth hormone in turner syndrome\". <i>J. Clin. Endocrinol. Metab</i>. <b>93</b> (2): 344\u201351. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1210/jc.2007-1723\">10.1210/jc.2007-1723</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18000090\">18000090</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Clin.+Endocrinol.+Metab.&amp;rft.atitle=Long-term+safety+of+recombinant+human+growth+hormone+in+turner+syndrome&amp;rft.volume=93&amp;rft.issue=2&amp;rft.pages=344-51&amp;rft.date=2008-02&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2007-1723&amp;rft_id=info%3Apmid%2F18000090&amp;rft.aulast=Bolar&amp;rft.aufirst=K&amp;rft.au=Hoffman%2C+AR&amp;rft.au=Maneatis%2C+T&amp;rft.au=Lippe%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17595258-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17595258_13-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA (September 2007). \"Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial\". <i>J. Clin. Endocrinol. Metab</i>. <b>92</b> (9): 3406\u201316. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1210/jc.2006-2874\">10.1210/jc.2006-2874</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17595258\">17595258</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Clin.+Endocrinol.+Metab.&amp;rft.atitle=Growth+hormone+treatment+of+early+growth+failure+in+toddlers+with+Turner+syndrome%3A+a+randomized%2C+controlled%2C+multicenter+trial&amp;rft.volume=92&amp;rft.issue=9&amp;rft.pages=3406-16&amp;rft.date=2007-09&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2006-2874&amp;rft_id=info%3Apmid%2F17595258&amp;rft.aulast=Davenport&amp;rft.aufirst=ML&amp;rft.au=Crowe%2C+BJ&amp;rft.au=Travers%2C+SH&amp;rft.au=Rubin%2C+K&amp;rft.au=Ross%2C+JL&amp;rft.au=Fechner%2C+PY&amp;rft.au=Gunther%2C+DF&amp;rft.au=Liu%2C+C&amp;rft.au=Geffner%2C+ME&amp;rft.au=Thrailkill%2C+K&amp;rft.au=Huseman%2C+C&amp;rft.au=Zagar%2C+AJ&amp;rft.au=Quigley%2C+CA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17971794-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17971794_14-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Backeljauw P (February 2008). \"Does growth hormone therapy before 4 years of age enhance the linear growth of girls with Turner's syndrome?\". <i>Nat Clin Pract Endocrinol Metab</i>. <b>4</b> (2): 78\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/ncpendmet0678\">10.1038/ncpendmet0678</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17971794\">17971794</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat+Clin+Pract+Endocrinol+Metab&amp;rft.atitle=Does+growth+hormone+therapy+before+4+years+of+age+enhance+the+linear+growth+of+girls+with+Turner%27s+syndrome%3F&amp;rft.volume=4&amp;rft.issue=2&amp;rft.pages=78-9&amp;rft.date=2008-02&amp;rft_id=info%3Adoi%2F10.1038%2Fncpendmet0678&amp;rft_id=info%3Apmid%2F17971794&amp;rft.au=Backeljauw+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.mayoclinic.com/health/prader-willi-syndrome/DS00922/DSECTION=treatments-and-drugs\">\"Prader-Willi syndrome - Symptoms and causes\"</a>. <i>mayoclinic.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">14 April</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=mayoclinic.com&amp;rft.atitle=Prader-Willi+syndrome+-+Symptoms+and+causes&amp;rft_id=http%3A%2F%2Fwww.mayoclinic.com%2Fhealth%2Fprader-willi-syndrome%2FDS00922%2FDSECTION%3Dtreatments-and-drugs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17823537-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17823537_16-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chatelain P, Carrascosa A, Bona G, Ferrandez-Longas A, Sippell W (2007). \"Growth hormone therapy for short children born small for gestational age\". <i>Horm. Res</i>. <b>68</b> (6): 300\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1159/000107935\">10.1159/000107935</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17823537\">17823537</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Horm.+Res.&amp;rft.atitle=Growth+hormone+therapy+for+short+children+born+small+for+gestational+age&amp;rft.volume=68&amp;rft.issue=6&amp;rft.pages=300-9&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1159%2F000107935&amp;rft_id=info%3Apmid%2F17823537&amp;rft.aulast=Chatelain&amp;rft.aufirst=P&amp;rft.au=Carrascosa%2C+A&amp;rft.au=Bona%2C+G&amp;rft.au=Ferrandez-Longas%2C+A&amp;rft.au=Sippell%2C+W&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid18040291-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid18040291_17-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Czernichow P (March 2008). \"Which children with idiopathic short stature should receive growth hormone therapy?\". <i>Nat Clin Pract Endocrinol Metab</i>. <b>4</b> (3): 118\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/ncpendmet0700\">10.1038/ncpendmet0700</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18040291\">18040291</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat+Clin+Pract+Endocrinol+Metab&amp;rft.atitle=Which+children+with+idiopathic+short+stature+should+receive+growth+hormone+therapy%3F&amp;rft.volume=4&amp;rft.issue=3&amp;rft.pages=118-9&amp;rft.date=2008-03&amp;rft_id=info%3Adoi%2F10.1038%2Fncpendmet0700&amp;rft_id=info%3Apmid%2F18040291&amp;rft.au=Czernichow+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17519313-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17519313_18-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hannon TS, Danadian K, Suprasongsin C, Arslanian SA (August 2007). \"Growth hormone treatment in adolescent males with idiopathic short stature: changes in body composition, protein, fat, and glucose metabolism\". <i>J. Clin. Endocrinol. Metab</i>. <b>92</b> (8): 3033\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1210/jc.2007-0308\">10.1210/jc.2007-0308</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17519313\">17519313</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Clin.+Endocrinol.+Metab.&amp;rft.atitle=Growth+hormone+treatment+in+adolescent+males+with+idiopathic+short+stature%3A+changes+in+body+composition%2C+protein%2C+fat%2C+and+glucose+metabolism&amp;rft.volume=92&amp;rft.issue=8&amp;rft.pages=3033-9&amp;rft.date=2007-08&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2007-0308&amp;rft_id=info%3Apmid%2F17519313&amp;rft.aulast=Hannon&amp;rft.aufirst=TS&amp;rft.au=Danadian%2C+K&amp;rft.au=Suprasongsin%2C+C&amp;rft.au=Arslanian%2C+SA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid12606730-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid12606730_19-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Drazen JM (February 2003). \"Inappropriate advertising of dietary supplements\". <i>N. Engl. J. Med</i>. <b>348</b> (9): 777\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMp030021\">10.1056/NEJMp030021</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12606730\">12606730</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=Inappropriate+advertising+of+dietary+supplements&amp;rft.volume=348&amp;rft.issue=9&amp;rft.pages=777-8&amp;rft.date=2003-02&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMp030021&amp;rft_id=info%3Apmid%2F12606730&amp;rft.au=Drazen+JM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid12606731-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid12606731_20-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Vance ML (February 2003). \"Can growth hormone prevent aging?\". <i>N. Engl. J. Med</i>. <b>348</b> (9): 779\u201380. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMp020186\">10.1056/NEJMp020186</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12606731\">12606731</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=Can+growth+hormone+prevent+aging%3F&amp;rft.volume=348&amp;rft.issue=9&amp;rft.pages=779-80&amp;rft.date=2003-02&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMp020186&amp;rft_id=info%3Apmid%2F12606731&amp;rft.au=Vance+ML&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid10477776-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid10477776_21-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ (September 1999). \"Increased mortality associated with growth hormone treatment in critically ill adults\". <i>N. Engl. J. Med</i>. <b>341</b> (11): 785\u201392. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJM199909093411102\">10.1056/NEJM199909093411102</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/10477776\">10477776</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=Increased+mortality+associated+with+growth+hormone+treatment+in+critically+ill+adults&amp;rft.volume=341&amp;rft.issue=11&amp;rft.pages=785-92&amp;rft.date=1999-09&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199909093411102&amp;rft_id=info%3Apmid%2F10477776&amp;rft.aulast=Takala&amp;rft.aufirst=J&amp;rft.au=Ruokonen%2C+E&amp;rft.au=Webster%2C+NR&amp;rft.au=Nielsen%2C+MS&amp;rft.au=Zandstra%2C+DF&amp;rft.au=Vundelinckx%2C+G&amp;rft.au=Hinds%2C+CJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid12679422-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid12679422_22-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L (April 2003). \"Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle\". <i>J. Clin. Endocrinol. Metab</i>. <b>88</b> (4): 1455\u201363. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1210/jc.2002-020542\">10.1210/jc.2002-020542</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12679422\">12679422</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Clin.+Endocrinol.+Metab.&amp;rft.atitle=Growth+hormone+replacement+therapy+induces+insulin+resistance+by+activating+the+glucose-fatty+acid+cycle&amp;rft.volume=88&amp;rft.issue=4&amp;rft.pages=1455-63&amp;rft.date=2003-04&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2002-020542&amp;rft_id=info%3Apmid%2F12679422&amp;rft.aulast=Bramnert&amp;rft.aufirst=M&amp;rft.au=Segerlantz%2C+M&amp;rft.au=Laurila%2C+E&amp;rft.au=Daugaard%2C+JR&amp;rft.au=Manhem%2C+P&amp;rft.au=Groop%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid21543424-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid21543424_23-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR (July 2011). \"Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis\". <i>J. Clin. Endocrinol. Metab</i>. <b>96</b> (7): 2255\u201361. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1210/jc.2011-0448\">10.1210/jc.2011-0448</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21543424\">21543424</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Clin.+Endocrinol.+Metab.&amp;rft.atitle=Prevalence+and+incidence+of+diabetes+mellitus+in+adult+patients+on+growth+hormone+replacement+for+growth+hormone+deficiency%3A+a+surveillance+database+analysis&amp;rft.volume=96&amp;rft.issue=7&amp;rft.pages=2255-61&amp;rft.date=2011-07&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2011-0448&amp;rft_id=info%3Apmid%2F21543424&amp;rft.aulast=Attanasio&amp;rft.aufirst=AF&amp;rft.au=Jung%2C+H&amp;rft.au=Mo%2C+D&amp;rft.au=Chanson%2C+P&amp;rft.au=Bouillon%2C+R&amp;rft.au=Ho%2C+KK&amp;rft.au=Lamberts%2C+SW&amp;rft.au=Clemmons%2C+DR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid21646285-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid21646285_24-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL (August 2011). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3132593\">\"Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study\"</a>. <i>Eur. J. Endocrinol</i>. <b>165</b> (2): 217\u201323. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1530/EJE-11-0286\">10.1530/EJE-11-0286</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3132593\">3132593</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21646285\">21646285</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eur.+J.+Endocrinol.&amp;rft.atitle=Assessment+of+primary+cancers+in+GH-treated+adult+hypopituitary+patients%3A+an+analysis+from+the+Hypopituitary+Control+and+Complications+Study&amp;rft.volume=165&amp;rft.issue=2&amp;rft.pages=217-23&amp;rft.date=2011-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3132593&amp;rft_id=info%3Apmid%2F21646285&amp;rft_id=info%3Adoi%2F10.1530%2FEJE-11-0286&amp;rft.aulast=Child&amp;rft.aufirst=CJ&amp;rft.au=Zimmermann%2C+AG&amp;rft.au=Woodmansee%2C+WW&amp;rft.au=Green%2C+DM&amp;rft.au=Li%2C+JJ&amp;rft.au=Jung%2C+H&amp;rft.au=Erfurth%2C+EM&amp;rft.au=Robison%2C+LL&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3132593&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-url_FDA_somatropin_Safety_Review-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-url_FDA_somatropin_Safety_Review_25-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237969.htm\">\"Recombinant Human Growth Hormone (somatropin): Ongoing Safety Review - Possible Increased Risk of Death\"</a>. <i>Safety Information</i>. U.S. Food and Drug Administration. 2011-04-08.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Safety+Information&amp;rft.atitle=Recombinant+Human+Growth+Hormone+%28somatropin%29%3A+Ongoing+Safety+Review+-+Possible+Increased+Risk+of+Death&amp;rft.date=2011-04-08&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FSafety%2FMedWatch%2FSafetyInformation%2FSafetyAlertsforHumanMedicalProducts%2Fucm237969.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.kefeibiotech.com/HGH\">\"HGH \u2013 Kefei Biotech HGH Steroids and Peptides\"</a>. <i>www.kefeibiotech.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">14 April</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.kefeibiotech.com&amp;rft.atitle=HGH+%E2%80%93+Kefei+Biotech+HGH+Steroids+and+Peptides&amp;rft_id=http%3A%2F%2Fwww.kefeibiotech.com%2FHGH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid2355952-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid2355952_27-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE (July 1990). \"Effects of human growth hormone in men over 60 years old\". <i>N. Engl. J. Med</i>. <b>323</b> (1): 1\u20136. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJM199007053230101\">10.1056/NEJM199007053230101</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/2355952\">2355952</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=Effects+of+human+growth+hormone+in+men+over+60+years+old&amp;rft.volume=323&amp;rft.issue=1&amp;rft.pages=1-6&amp;rft.date=1990-07&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199007053230101&amp;rft_id=info%3Apmid%2F2355952&amp;rft.aulast=Rudman&amp;rft.aufirst=D&amp;rft.au=Feller%2C+AG&amp;rft.au=Nagraj%2C+HS&amp;rft.au=Gergans%2C+GA&amp;rft.au=Lalitha%2C+PY&amp;rft.au=Goldberg%2C+AF&amp;rft.au=Schlenker%2C+RA&amp;rft.au=Cohn%2C+L&amp;rft.au=Rudman%2C+IW&amp;rft.au=Mattson%2C+DE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\">Ronald Klatz and Carol Kahn. Grow Young With Hgh: The Amazing Medically Proven Plan to&#160;: Lose Fat, Build Muscle, Reverse the Effects of Aging, Strengthen the Immune System, Improve Sexual Performance. Harpercollins; 1st edition (April 1997) <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0060186828\" title=\"Special:BookSources/0060186828\">0060186828</a></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\">Blackman MR, et al (2002) <a rel=\"nofollow\" class=\"external text\" href=\"http://jama.jamanetwork.com/article.aspx?articleid=1108358\">Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.</a> JAMA 288(18):2282-92.</span>\n</li>\n<li id=\"cite_note-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-30\">^</a></b></span> <span class=\"reference-text\">Olshansky SJ et al (2002) <a rel=\"nofollow\" class=\"external text\" href=\"http://webmedia.unmc.edu/alliedhealth/nichols/Postition%20Statement%20Human%20Aging.pdf\">Position Statement on Human Aging</a> Journal of Gerontology 57A(8):B292\u2013B297</span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\">Leona Cuttler (2005) <a rel=\"nofollow\" class=\"external text\" href=\"http://jcem.endojournals.org/content/90/9/5502.full\">Editorial: Safety and Efficacy of Growth Hormone Treatment for Idiopathic Short Stature</a>. The Journal of Clinical Endocrinology &amp; Metabolism 90(9):5502-5504</span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.gene.com/gene/about/ir/historical/product-sales/nutropin.html\">http://www.gene.com/gene/about/ir/historical/product-sales/nutropin.html</a></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Growth_hormone_therapy&amp;action=edit&amp;section=11\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<style data-mw-deduplicate=\"TemplateStyles:r853264625\">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class=\"refbegin\" style=\"\">\n<ul><li><cite class=\"citation journal\">Weiss JO, Hall JG (September 1991). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.gghjournal.com/pdf/volume_7/3/feature_3.pdf\">\"Support Groups for Individuals with Growth Problems and their Families\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Growth Genet Horm</i>. <b>7</b> (3).</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Growth+Genet+Horm&amp;rft.atitle=Support+Groups+for+Individuals+with+Growth+Problems+and+their+Families&amp;rft.volume=7&amp;rft.issue=3&amp;rft.date=1991-09&amp;rft.aulast=Weiss&amp;rft.aufirst=JO&amp;rft.au=Hall%2C+JG&amp;rft_id=http%3A%2F%2Fwww.gghjournal.com%2Fpdf%2Fvolume_7%2F3%2Ffeature_3.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation journal\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.gghjournal.com/pdf/volume_14/14-1/14_1_related_ab2.pdf\">\"Considerations Related to the Use of Recombinant Human Growth Hormone in Children\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Growth Genet Horm</i>. <b>14</b> (1). April 1998.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Growth+Genet+Horm&amp;rft.atitle=Considerations+Related+to+the+Use+of+Recombinant+Human+Growth+Hormone+in+Children&amp;rft.volume=14&amp;rft.issue=1&amp;rft.date=1998-04&amp;rft_id=http%3A%2F%2Fwww.gghjournal.com%2Fpdf%2Fvolume_14%2F14-1%2F14_1_related_ab2.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGrowth+hormone+therapy\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n</div>\n<p><br />\n</p>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Pharmacological_body_alteration\" style=\"padding:3px\"><table class=\"nowraplinks hlist collapsible collapsed navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Pharmacological_body_alteration\" title=\"Template:Pharmacological body alteration\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Pharmacological_body_alteration\" title=\"Template talk:Pharmacological body alteration\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Pharmacological_body_alteration&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Pharmacological_body_alteration\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">Pharmacological</a> <a href=\"/wiki/Body_alteration\" class=\"mw-redirect\" title=\"Body alteration\">body alteration</a></div></th></tr><tr><td colspan=\"2\" class=\"navbox-list navbox-odd hlist\" style=\"width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Bodybuilding_supplement\" title=\"Bodybuilding supplement\">Bodybuilding supplement</a></li>\n<li><a href=\"/wiki/Breast_enlargement_supplement\" title=\"Breast enlargement supplement\">Breast enlargement supplement</a></li>\n<li><a href=\"/wiki/Clitoral_enlargement_methods\" title=\"Clitoral enlargement methods\">Clitoris enlargement</a></li>\n<li><a href=\"/wiki/Ergogenic_use_of_anabolic_steroids\" title=\"Ergogenic use of anabolic steroids\">Ergogenic use of anabolic steroids</a></li>\n<li><a class=\"mw-selflink selflink\">Growth hormone therapy</a></li>\n<li><a href=\"/wiki/Hormonal_breast_enhancement\" title=\"Hormonal breast enhancement\">Hormonal breast enhancement</a></li>\n<li><a href=\"/wiki/Transgender_hormone_therapy\" title=\"Transgender hormone therapy\">Transgender hormone therapy</a>\n<ul><li><a href=\"/wiki/Feminizing_hormone_therapy\" class=\"mw-redirect\" title=\"Feminizing hormone therapy\">Feminizing hormone therapy</a></li>\n<li><a href=\"/wiki/Masculinizing_hormone_therapy\" class=\"mw-redirect\" title=\"Masculinizing hormone therapy\">Masculinizing hormone therapy</a></li></ul></li>\n<li><a href=\"/wiki/Penis_enlargement\" title=\"Penis enlargement\">Penis enlargement</a></li>\n<li><a href=\"/wiki/Performance-enhancing_substance\" title=\"Performance-enhancing substance\">Performance-enhancing substance</a></li></ul>\n</div></td></tr></tbody></table></div>\n\n<!-- \nNewPP limit report\nParsed by mw2166\nCached time: 20180912152608\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.648 seconds\nReal time usage: 0.729 seconds\nPreprocessor visited node count: 3118/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 75187/2097152 bytes\nTemplate argument size: 5259/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 4/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 40420/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.332/10.000 seconds\nLua memory usage: 8.14 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  630.568      1 -total\n 44.10%  278.081      1 Template:Reflist\n 28.43%  179.286     21 Template:Cite_journal\n 24.42%  153.989     10 Template:Citation_needed\n 21.97%  138.529     10 Template:Fix\n 11.35%   71.590     10 Template:Delink\n 11.03%   69.544      1 Template:Infobox_medical_intervention\n 10.39%   65.542      1 Template:Infobox\n  9.21%   58.062     20 Template:Category_handler\n  5.93%   37.411      1 Template:ISBN\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:622411-0!canonical and timestamp 20180912152607 and revision id 859219593\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D8%B9%D9%84%D8%A7%D8%AC_%D9%87%D8%B1%D9%85%D9%88%D9%86_%D8%A7%D9%84%D9%86%D9%85%D9%88","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0639\u0644\u0627\u062c \u0647\u0631\u0645\u0648\u0646 \u0627\u0644\u0646\u0645\u0648"}],"categories":[{"sortkey":"Growth Hormone Treatment","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"Growth Hormone Treatment","hidden":"","*":"Articles_with_unsourced_statements_from_January_2009"},{"sortkey":"Growth Hormone Treatment","hidden":"","*":"Articles_with_unsourced_statements_from_November_2008"},{"sortkey":"Growth Hormone Treatment","hidden":"","*":"Articles_with_unsourced_statements_from_November_2017"},{"sortkey":"Growth Hormone Treatment","hidden":"","*":"Articles_with_unsourced_statements_from_June_2011"},{"sortkey":"Growth Hormone Treatment","*":"Growth_hormones"},{"sortkey":"Growth Hormone Treatment","*":"Pediatrics"},{"sortkey":"Growth Hormone Treatment","*":"Endocrine_procedures"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from January 2009"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2008"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2017"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from June 2011"},{"ns":10,"exists":"","*":"Template:Pharmacological body alteration"},{"ns":0,"exists":"","*":"Acromegaly"},{"ns":0,"exists":"","*":"Adipose tissue"},{"ns":0,"exists":"","*":"American Academy of Anti-Aging Medicine"},{"ns":0,"exists":"","*":"Amino acid"},{"ns":0,"exists":"","*":"Anabolic steroid"},{"ns":0,"exists":"","*":"Autopsy"},{"ns":0,"exists":"","*":"Biochemistry"},{"ns":0,"exists":"","*":"Bioethics"},{"ns":0,"exists":"","*":"Blood lipid"},{"ns":0,"exists":"","*":"Body alteration"},{"ns":0,"exists":"","*":"Bodybuilding supplement"},{"ns":0,"exists":"","*":"Bone density"},{"ns":0,"exists":"","*":"Bovine somatotropin"},{"ns":0,"exists":"","*":"Breast enlargement supplement"},{"ns":0,"exists":"","*":"Cachexia"},{"ns":0,"exists":"","*":"Cadaver"},{"ns":0,"exists":"","*":"Cancer"},{"ns":0,"exists":"","*":"Catch-up growth"},{"ns":0,"exists":"","*":"Cell (biology)"},{"ns":0,"exists":"","*":"Cell growth"},{"ns":0,"exists":"","*":"Chronic renal failure"},{"ns":0,"exists":"","*":"Circulatory system"},{"ns":0,"exists":"","*":"Clitoral enlargement methods"},{"ns":0,"exists":"","*":"Cornea transplantation"},{"ns":0,"exists":"","*":"Creutzfeldt\u2013Jakob disease"},{"ns":0,"exists":"","*":"Dehydroepiandrosterone"},{"ns":0,"exists":"","*":"Delayed puberty"},{"ns":0,"exists":"","*":"Dementia"},{"ns":0,"exists":"","*":"Diabetes mellitus"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Eli Lilly and Company"},{"ns":0,"exists":"","*":"Ergogenic use of anabolic steroids"},{"ns":0,"exists":"","*":"Estrogen"},{"ns":0,"exists":"","*":"Feminizing hormone therapy"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Gene"},{"ns":0,"exists":"","*":"Genentech"},{"ns":0,"exists":"","*":"General Tom Thumb"},{"ns":0,"exists":"","*":"Gigantism"},{"ns":0,"exists":"","*":"Growth hormone"},{"ns":0,"exists":"","*":"Growth hormone deficiency"},{"ns":0,"exists":"","*":"Growth hormone in sports"},{"ns":0,"exists":"","*":"HGH controversies"},{"ns":0,"exists":"","*":"Hormonal breast enhancement"},{"ns":0,"exists":"","*":"Hormone therapy"},{"ns":0,"exists":"","*":"IGF1"},{"ns":0,"exists":"","*":"Idiopathic short stature"},{"ns":0,"exists":"","*":"Immune system"},{"ns":0,"exists":"","*":"Insulin"},{"ns":0,"exists":"","*":"Insulin sensitivity"},{"ns":0,"exists":"","*":"Intensive care"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"International nonproprietary name"},{"ns":0,"exists":"","*":"Intrauterine growth retardation"},{"ns":0,"exists":"","*":"Mad cow disease"},{"ns":0,"exists":"","*":"Masculinizing hormone therapy"},{"ns":0,"exists":"","*":"Medical diagnosis"},{"ns":0,"exists":"","*":"Merck Serono"},{"ns":0,"exists":"","*":"Methionine"},{"ns":0,"exists":"","*":"Midget"},{"ns":0,"exists":"","*":"Motor development"},{"ns":0,"exists":"","*":"National Cooperative Growth Study"},{"ns":0,"exists":"","*":"National Institutes of Health"},{"ns":0,"exists":"","*":"Neurosurgery"},{"ns":0,"exists":"","*":"Novo Nordisk"},{"ns":0,"exists":"","*":"Off-label use"},{"ns":0,"exists":"","*":"Organ transplant"},{"ns":0,"exists":"","*":"Orphan drug"},{"ns":0,"exists":"","*":"P. T. Barnum"},{"ns":0,"exists":"","*":"Pancreas"},{"ns":0,"exists":"","*":"Pathologist"},{"ns":0,"exists":"","*":"Pediatric endocrinologist"},{"ns":0,"exists":"","*":"Pediatric endocrinology"},{"ns":0,"exists":"","*":"Penis enlargement"},{"ns":0,"exists":"","*":"Peptide hormone"},{"ns":0,"exists":"","*":"Performance-enhancing substance"},{"ns":0,"exists":"","*":"Pfizer"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Pituitary"},{"ns":0,"exists":"","*":"Pituitary gland"},{"ns":0,"exists":"","*":"Postmarketing surveillance"},{"ns":0,"exists":"","*":"Prader-Willi syndrome"},{"ns":0,"exists":"","*":"Prader\u2013Willi syndrome"},{"ns":0,"exists":"","*":"Prescription medication"},{"ns":0,"exists":"","*":"Primary care physician"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Quality of life"},{"ns":0,"exists":"","*":"RHGH"},{"ns":0,"exists":"","*":"Recombinant DNA"},{"ns":0,"exists":"","*":"Recombinant DNA technology"},{"ns":0,"exists":"","*":"Rh blood group system"},{"ns":0,"exists":"","*":"Rhesus macaque"},{"ns":0,"exists":"","*":"Saizen"},{"ns":0,"exists":"","*":"Serono"},{"ns":0,"exists":"","*":"Short stature"},{"ns":0,"exists":"","*":"Short stature homeobox gene"},{"ns":0,"exists":"","*":"Somatrem"},{"ns":0,"exists":"","*":"Specialty (medicine)"},{"ns":0,"exists":"","*":"Spongiform encephalopathy"},{"ns":0,"exists":"","*":"Syringe"},{"ns":0,"exists":"","*":"Testosterone (medication)"},{"ns":0,"exists":"","*":"Teva Pharmaceutical Industries"},{"ns":0,"exists":"","*":"The Endocrine Society"},{"ns":0,"exists":"","*":"Transgender hormone therapy"},{"ns":0,"exists":"","*":"Turner syndrome"},{"ns":0,"*":"National Pituitary Agency"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":11,"exists":"","*":"Template talk:Pharmacological body alteration"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox medical intervention"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:PAGENAMEBASE"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Convert"},{"ns":10,"exists":"","*":"Template:Height"},{"ns":10,"exists":"","*":"Template:Rp"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:ISBN"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Error-small"},{"ns":10,"exists":"","*":"Template:Tl"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Refbegin"},{"ns":10,"exists":"","*":"Template:Refbegin/styles.css"},{"ns":10,"exists":"","*":"Template:Refend"},{"ns":10,"exists":"","*":"Template:Pharmacological body alteration"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:Wikidata"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:I18n"},{"ns":828,"*":"Module:Infobox/i18n"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:Convert"},{"ns":828,"exists":"","*":"Module:Convert/data"},{"ns":828,"exists":"","*":"Module:Convert/text"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check isxn"},{"ns":828,"exists":"","*":"Module:Error"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Navbox"}],"images":["Lock-green.svg"],"externallinks":["http://www.endo-society.org/guidelines/upload/Evaluation-treatment-of-Adult-Growth-Hormone-Deficiency-Clinical-Practice-Guideline-NonCME.pdf","//doi.org/10.1530/eje.1.02317","//www.ncbi.nlm.nih.gov/pubmed/17218726","//doi.org/10.1179/acb.2010.002","//www.ncbi.nlm.nih.gov/pubmed/20373593","//doi.org/10.1046/j.1365-2265.2001.01275.x","//www.ncbi.nlm.nih.gov/pubmed/11422104","//doi.org/10.1159/000023531","//www.ncbi.nlm.nih.gov/pubmed/10971102","//doi.org/10.1210/jc.2006-1487","//www.ncbi.nlm.nih.gov/pubmed/17284638","//doi.org/10.1677/JOE-10-0126","//www.ncbi.nlm.nih.gov/pubmed/20696696","//doi.org/10.1210/jc.2007-1723","//www.ncbi.nlm.nih.gov/pubmed/18000090","//doi.org/10.1210/jc.2006-2874","//www.ncbi.nlm.nih.gov/pubmed/17595258","//doi.org/10.1038/ncpendmet0678","//www.ncbi.nlm.nih.gov/pubmed/17971794","http://www.mayoclinic.com/health/prader-willi-syndrome/DS00922/DSECTION=treatments-and-drugs","//doi.org/10.1159/000107935","//www.ncbi.nlm.nih.gov/pubmed/17823537","//doi.org/10.1038/ncpendmet0700","//www.ncbi.nlm.nih.gov/pubmed/18040291","//doi.org/10.1210/jc.2007-0308","//www.ncbi.nlm.nih.gov/pubmed/17519313","//doi.org/10.1056/NEJMp030021","//www.ncbi.nlm.nih.gov/pubmed/12606730","//doi.org/10.1056/NEJMp020186","//www.ncbi.nlm.nih.gov/pubmed/12606731","//doi.org/10.1056/NEJM199909093411102","//www.ncbi.nlm.nih.gov/pubmed/10477776","//doi.org/10.1210/jc.2002-020542","//www.ncbi.nlm.nih.gov/pubmed/12679422","//doi.org/10.1210/jc.2011-0448","//www.ncbi.nlm.nih.gov/pubmed/21543424","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3132593","//doi.org/10.1530/EJE-11-0286","//www.ncbi.nlm.nih.gov/pubmed/21646285","http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237969.htm","http://www.kefeibiotech.com/HGH","//doi.org/10.1056/NEJM199007053230101","//www.ncbi.nlm.nih.gov/pubmed/2355952","http://jama.jamanetwork.com/article.aspx?articleid=1108358","http://webmedia.unmc.edu/alliedhealth/nichols/Postition%20Statement%20Human%20Aging.pdf","http://jcem.endojournals.org/content/90/9/5502.full","http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019640s068lbl.pdf","http://www.gene.com/gene/products/information/opportunistic/nutropin/insert.jsp","http://www.pfizer.com/files/products/uspi_genotropin.pdf","http://www.serostim.com/Files/PDFs/Full_Prescribing_Information.pdf","http://www.gene.com/gene/about/ir/historical/product-sales/nutropin.html","http://www.gghjournal.com/pdf/volume_7/3/feature_3.pdf","http://www.gghjournal.com/pdf/volume_14/14-1/14_1_related_ab2.pdf"],"sections":[{"toclevel":1,"level":"2","line":"Medical uses","number":"1","index":"1","fromtitle":"Growth_hormone_therapy","byteoffset":1351,"anchor":"Medical_uses"},{"toclevel":2,"level":"3","line":"HGH deficiency in children","number":"1.1","index":"2","fromtitle":"Growth_hormone_therapy","byteoffset":1369,"anchor":"HGH_deficiency_in_children"},{"toclevel":2,"level":"3","line":"HGH deficiency in adults","number":"1.2","index":"3","fromtitle":"Growth_hormone_therapy","byteoffset":3351,"anchor":"HGH_deficiency_in_adults"},{"toclevel":2,"level":"3","line":"Other","number":"1.3","index":"4","fromtitle":"Growth_hormone_therapy","byteoffset":7319,"anchor":"Other"},{"toclevel":1,"level":"2","line":"Adverse effects","number":"2","index":"5","fromtitle":"Growth_hormone_therapy","byteoffset":14060,"anchor":"Adverse_effects"},{"toclevel":1,"level":"2","line":"History","number":"3","index":"6","fromtitle":"Growth_hormone_therapy","byteoffset":18776,"anchor":"History"},{"toclevel":2,"level":"3","line":"Extraction for treatment","number":"3.1","index":"7","fromtitle":"Growth_hormone_therapy","byteoffset":19948,"anchor":"Extraction_for_treatment"},{"toclevel":2,"level":"3","line":"Recombinant human growth hormone (rHGH)","number":"3.2","index":"8","fromtitle":"Growth_hormone_therapy","byteoffset":23960,"anchor":"Recombinant_human_growth_hormone_(rHGH)"},{"toclevel":1,"level":"2","line":"Terminology","number":"4","index":"9","fromtitle":"Growth_hormone_therapy","byteoffset":34010,"anchor":"Terminology"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"10","fromtitle":"Growth_hormone_therapy","byteoffset":36038,"anchor":"References"},{"toclevel":1,"level":"2","line":"Further reading","number":"6","index":"11","fromtitle":"Growth_hormone_therapy","byteoffset":36071,"anchor":"Further_reading"}],"parsewarnings":[],"displaytitle":"Growth hormone therapy","iwlinks":[{"prefix":"d","url":"https://www.wikidata.org/wiki/Q5611754","*":"d:Q5611754"}],"properties":[{"name":"defaultsort","*":"Growth Hormone Treatment"},{"name":"wikibase_item","*":"Q5611754"}]}}